allergy-clinical-immunology-2017-posters-abstracts

14 / 25

Page 66
conferenceseries.com
Volume 8, Issue 3(Suppl) J Allergy Ther, an open access journal
ISSN: 2155-6121 Allergy-Clinical Immunology 2017
September 07-08, 2017
September 07-08, 2017 | Edinburgh, Scotland
ALLERGY, ASTHMA & CLINICAL IMMUNOLOGY
11th International Conference on
Molecular approach to optimal choice of specific immunotherapy of patients with sensitization to
weed pollen allergens
Zubchenko S and Danylo Halytsky
Danylo Halytsky Lviv National Medical University, Ukraine
Introduction: The problem of pollen allergy including pollen of weeds is important for the population of Western Ukraine,
including Lviv region.
Aim: Aimof this study is to compare possibility of SPT and component diagnostics to select appropriate specific immunotherapy.
Materials & Methods: 48 patients of both the sexes, aged 18-65 years, residents of Lviv region with seasonal allergic rhinitis/
conjunctivitis, were selected according to primary stay in the first week of August this year. SPT performed to extract pollen
allergens from local sources including a mixture of weeds, grasses and extracts of ambrosia, ragweed and timothy. ImmunoCAP
was used for molecular researches of sIgE.
Results: In 50% of patients, positive SPT was found to mixture of weed, extracts of ambrosia, ragweed and grass mixtures.
This indicated co-sensitization to various sources of allergens. 30% of patients had mono-sensitization to weeds pollen, and
20% mono-sensitization to grass pollen. However, simultaneous sensitization to pollen of ambrosia, ragweed and timothy
has not been proven by molecular researches. Instead, 20% of patients identified sensitization to ragweed and ambrosia, 30%
of people identified mono-sensitization to ambrosia and 20% mono-sensitization to ragweed. Most (70%) of patients with
mono-sensitization to pollen of weeds identified specific IgE to Art v1 and/or Art v3, and/or Amb a1. False positive results of
SPT indicated that co-sensitization to grasses and weeds can be explained by the presence of sIgE for cross-reactive markers of
profilin Phl p 12 and polcalcin-Phl p 7.
Conclusion: On the basis of SPT and molecular researches, doctor takes a fundamentally different decision on the selection
of extracts for specific allergen immunotherapy. Optimal allergic immunotherapy is based on the identification of primary
sensitizer and cross-reactivity markers.
Biography
Zubchenko S is pursuing her PhD in Medical Sciences and is an Assistant Professor at Danylo Halytsky Lviv National Medical University in Department of Clinical
Immunology and Allergology. She is a Clinical Immunologist and Allergologist. She was a participant of numerous congresses, conferences, training courses, which
are organized by EAACI.
Zubchenko S et al., J Allergy Ther 2017, 8:3(Suppl)
DOI: 10.4172/2155-6121-C1-006